Table 1 Baseline Characteristics
Variables | Total Cohort (n = 100) | p Value | ||
|---|---|---|---|---|
Control Group (n = 30) | Non-responder Group (n = 32) | Responder Group (n = 38) | ||
Age, yrs | 46 ± 1 | 62 ± 2 | 62.35 ± 1.67 | < 0.0001 |
Female/Male | 12/18(1:1.5) | 8/24(1:3) | 13/25(1:1.9) | 0.01 |
NYHA functional class | / | 3.03 ± 0.67 | 2.85 ± 0.46 | 0.17 |
QRS, ms | 81 ± 2.52 | 149 ± 6.37 | 151 ± 5.26 | < 0.0001 |
Ischemic etiology | / | 4(12%) | 4(10%) | 0.64 |
LVEF, % | 69.45 ± 0.73 | 26.50 ± 1.91 | 26.45 ± 1.05 | < 0.0001 |
LVEDV, ml | 62.50 ± 1.93 | 282.30 ± 21.56 | 203.00 ± 11.30*** | < 0.0001 |
LVESV, ml | 18.80 ± 0.61 | 210.40 ± 20.14 | 150.20 ± 9.29** | < 0.0001 |
TTO-16-SD, % | 2.85 ± 0.23 | 9.65 ± 0.85 | 14.04 ± 2.01* | < 0.0001 |
TTP-16-SD, % | 3.73 ± 0.18 | 12.45 ± 1.12 | 16.83 ± 2.90 | < 0.0001 |